21.68
21.68 (0%)
As of Feb 14, 2025
Imara Inc. [ELVN]
Source:
Company Overview
Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being.
| Country | United States |
| Headquarters | boulder, colorado |
| Phone Number | (720) 647-8519 |
| Industry | manufacturing |
| CEO | Samuel Kintz |
| Website | www.enliventherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-104.6 |
| Net Income | $-89 |
| Net Cash | $24 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -29.8% |
| Profit as % of Stockholder Equity | -28.7% |
Management Effectiveness
| Return on Equity | -28.7% |
| Return on Assets | -27.3% |
| Turnover Ratio | |
| EBITA | $-104.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $325.8 |
| Total Liabilities | $15.9 |
| Operating Cash Flow | $-73.2 |
| Investing Cash Flow | $-36 |
| Financing Cash Flow | $133.2 |
